Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention

Journal of the American College of Cardiology

Volumn 61, Issue 1, 2013, Pages 23-34

  Ang, Lawrence ^a   Thani, Khalid Bin ^a   Ilapakurti, Manjusha ^a   Lee, Michael S ^b   Palakodeti, Vachaspathi ^a   Mahmud, Ehtisham ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

clopidogrel; fibrinogen; periprocedural myocardial infarction; platelet reactivity; VerifyNow

Indexed keywords

C REACTIVE PROTEIN; CLOPIDOGREL; CREATINE KINASE MB; FIBRINOGEN; TROPONIN I; TROPONIN T;

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPROCEDURAL MYOCARDIAL INFARCTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE COUNT;

AGED; BLOOD PLATELETS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PREMEDICATION; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TICLOPIDINE; TROPONIN;

EID: 84872050252     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.09.037     Document Type: Article

References (35)

1. S. Yusuf, F. Zhao, S.R. Mehta Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
2. G.N. Levine, E.R. Bates, J.C. Blankenship 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122 2574-609
3. E. Mahmud, L. Ang Monitoring antiplatelet therapy during peripheral vascular and coronary interventions Tech Vasc Interv Radiol 9 2006 56 63
4. L. Bonello, U.S. Tantry, R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
5. Stone GW. Patients with acute coronary syndrome and/or diabetes who show poor response to dual antiplatelet therapy as measured by platelet function testing are at greater risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents. Results of the ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) Registry. Paper presented at: the 23rd Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium; November 9, 2011; San Francisco, CA.
6. T.F. Althoff, M. Fischer, E. Langer, S. Zeimer, G. Baumann Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients Thromb Res 1255 2010 e190 e196
7. M.A. Arnau Vives, J. Rueda Soriano, L.V. Martínez Dolz Prognostic value of fibrinogen in patients admitted with suspected unstable angina and non-q-wave myocardial infarction Rev Esp Cardiol 55 2002 622 630
8. H. Toss, B. Lindahl, A. Siegbahn, L. Wallentin FRISC Study Group Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease Fragmin during Instability in Coronary Artery Disease Circulation 96 1997 4204 4210
9. P.W. Verheggen, M.P. de Maat, V.M. Cats Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function Eur Heart J 20 1999 567 574
10. R.C. Becker, C.P. Cannon, E.G. Bovill Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial) Am J Cardiol 78 1996 142 147
11. S.G. Thompson, J. Kienast, S.D. Pyke, F. Haverkate, J.C. van de Loo European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris N Engl J Med 332 1995 635 641
12. W.B. Kannel, P.A. Wolf, W.P. Castelli, R.B. D'Agostino Fibrinogen and risk of cardiovascular disease The Framingham Study JAMA 258 1987 1183 1186
13. T.W. Meade, S. Mellows, M. Brozovic Haemostatic function and ischemic heart disease: principal results of the Northwick Park Study Lancet 2 1986 533 537
14. A.J. Lee, G.D. Lowe, M. Woodward, H. Tunstall-Pedoe Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study Br Heart J 69 1993 338 342
15. Fibrinogen Study Collaboration Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis JAMA 294 2005 1799 1809
16. L. Ang, E. Mahmud Monitoring oral antiplatelet therapy: is it justified? Ther Adv Cardiovasc Dis 2 2008 485 496
17. L. Ang, V. Palakodeti, A. Khalid Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel J Am Coll Cardiol 52 2008 1052 1059
18. M. Valgimigli, G. Campo, N. de Cesare Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 2009 3215 3222
19. K. Thygesen, J.S. Alpert, H.D. White Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Universal definition of myocardial infarction J Am Coll Cardiol 50 2007 2173 2195
20. M.J. Price, P.B. Berger, P.S. Teirstein GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
21. M.J. Price, D.J. Angiolillo, P.S. Teirstein Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial Circulation 124 2011 1132 1137
22. A.J. Reininger Function of von Willebrand factor in haemostasis and thrombosis Haemophilia 14 2008 11 26
23. J.D. Wencel-Drake, R.G. Painter, T.S. Zimmerman, M.H. Ginsberg Ultrastructural localization of human platelet thrombospondin, fibrinogen, fibronectin, and von Willebrand factor in frozen thin section Blood 65 1985 929 938
24. J.C. Kaski, D.J. Fernández-Bergés, L. Consuegra-Sanchez A comparative study of biomarkers for risk prediction in acute coronary syndrome: results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study Atherosclerosis 212 2010 636 643
25. G. Parodi, R. Marcucci, R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
26. E. Mahmud, J.J. Cavendish, S. Tsimikas Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention J Am Coll Cardiol 49 2007 2164 2171
27. I. Bernlochner, S. Steinhubl, S. Braun Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment Thomb Haemost 104 2010 1193 1200
28. G. Patti, A. Nusca, F. Mangiacapra Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol 52 2008 1128 1133
29. R. Marcucci, A.M. Gori, R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 342
30. N.J. Breet, J.W. van Werkum, H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
31. M.J. Price, S. Endemann, R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
32. T. Cuisset, C. Frere, J. Quilici High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes Thromb Haemost 97 2007 282 287
33. C. Frere, T. Cuisset, J. Quilici ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome Throm Haemost 98 2007 838 843
34. P. Buonamici, R. Marcucci, A. Miglironi Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317
35. T. Cuisset, C. Frere, J. Quilici Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients Am J Cardiol 104 2009 1078 1082